• Nektar Therapeutics (NasdaqCM: NKTR) was recently added to a broad suite of FTSE Russell indices, including the Russell 2000, Russell 2500, Russell 3000 and related growth, value, and small-cap benchmark variants, following the latest index reconstitution completed on 27 June 2026.
• This sweeping inclusion across multiple small-cap and style indices can reshape Nektar’s investor base, as passive index-tracking and benchmark-aware funds adjust their portfolios to reflect the new membership.
• We’ll now examine how Nektar’s broad FTSE Russell index inclusion, especially in core small-cap benchmarks, reframes its existing investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Nektar Therapeutics Investment Narrative Recap

To own Nektar today, you have to believe that REZPEG can eventually translate its clinical profile into a viable commercial asset despite the company’s ongoing losses and reliance on external capital. The broad FTSE Russell index additions are more about visibility and trading liquidity than fundamentals, and they do not materially change the near term clinical and regulatory catalyst around REZPEG or the key risk of continued cash burn and potential future dilution.

Among recent announcements, the positive 36 week maintenance data from the Phase 2b REZOLVE AD trial stands out as most relevant. Index inclusion may draw more attention from small cap and healthcare focused funds just as Nektar advances toward the planned Phase 3 ZENITH AD program, putting a brighter spotlight on whether REZPEG’s longer term efficacy and safety profile can justify ongoing R&D spend and support the company’s pre commercial valuation.

Yet behind the index additions, one issue investors should be aware of is the ongoing risk that persistent losses and future funding needs could...

Nektar Therapeutics' narrative projects $54.9 million revenue and $10.7 million earnings by 2029. This implies fairly flat yearly revenue growth and an earnings increase of about $168.8 million from -$158.1 million today.

Uncover how Nektar Therapeutics' forecasts yield a $153.25 fair value, a 138% upside to its current price.

Exploring Other Perspectives

While consensus focuses on REZPEG as a key but uncertain catalyst, the most bullish analysts once projected revenue reaching about US$136,000,000 by 2029, showing how optimistic views on Nektar’s cash burn risks and clinical timelines can differ sharply and may now shift again after the broad Russell index inclusions.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

No Opportunity In Nektar Therapeutics?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.